Boston Scientific (NYSE:BSX) Stock Price Target Lowered at UBS Group

Boston Scientific (NYSE:BSX) had its price objective decreased by UBS Group from $67.00 to $57.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. UBS Group‘s price target would indicate a potential upside of 35.55% from the company’s previous close.

Several other research firms have also commented on BSX. Mizuho set a $50.00 target price on Boston Scientific in a research note on Thursday. Jefferies Financial Group lowered Boston Scientific from a “buy” rating to a “hold” rating and set a $46.00 price target on the stock. in a research note on Wednesday. Oppenheimer cut Boston Scientific from an “outperform” rating to a “market perform” rating in a report on Thursday. The Goldman Sachs Group dropped their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Boston Scientific in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.17.

Boston Scientific Trading Down 0.9%

BSX stock traded down $0.38 during midday trading on Thursday, hitting $42.05. The stock had a trading volume of 18,487,376 shares, compared to its average volume of 18,669,098. The firm has a market cap of $60.94 billion, a PE ratio of 17.01, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $105.65. The company’s 50-day moving average price is $45.12 and its 200 day moving average price is $57.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific will post 3.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Edward Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Habiger purchased 2,100 shares of the stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific in the second quarter worth $2,156,233,000. Janus Henderson Group PLC raised its stake in shares of Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the period. Amundi raised its stake in shares of Boston Scientific by 13.8% in the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after acquiring an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after acquiring an additional 2,856,040 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, up approximately 1.5% year over year and above the $5.07 billion analyst estimate. Adjusted EPS of $0.73 matched consensus, while management highlighted continued long-term investment and new clinical and regulatory milestones. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Analyst views remain mixed rather than uniformly bearish. Robert W. Baird raised its price target to $51 and maintained an outperform rating, while BTIG kept a buy rating with a reduced $49 target. Recent insider purchases, including a sizable purchase by CEO Michael Mahoney, may also offer some support for investor sentiment.
• Neutral Sentiment: Several firms adjusted their expectations after the results. Wells Fargo lowered its target to $45 and retained an equal-weight rating; Needham cut its target to $48 but kept a buy rating; and JPMorgan downgraded the stock to neutral with a $46 target. Oppenheimer also moved from outperform to market perform. Analysts revise forecasts on Boston Scientific
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to disrupt operations. Management lowered its full-year 2026 outlook to approximately 4.25% reported sales growth and expects fourth-quarter reported and organic sales to decline 1% to 3%. Fourth-quarter adjusted EPS guidance of $0.77 to $0.79 was below market expectations. Boston Scientific earnings and cybersecurity impact
• Negative Sentiment: Management warned that growth could remain challenging through 2027 because of cybersecurity-related rebuilding, weakness in electrophysiology and WATCHMAN heart-device sales, and pricing pressure in China. Contracting margins and lower EPS guidance have therefore outweighed the quarterly revenue beat, pressuring BSX shares.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.